


Ask a doctor about a prescription for OLMESARTAN/HYDROCHLOROTHIAZIDE STADA 20 mg/12.5 mg FILM-COATED TABLETS
Package Leaflet: Information for the Patient
Olmesartan/Hydrochlorothiazide Stada 20 mg/12.5 mg Film-Coated Tablets EFG
olmesartan medoxomil / hydrochlorothiazide
Read the entire package leaflet carefully before starting to take this medication, as it contains important information for you.
Contents of the Package Leaflet
Olmesartan/Hydrochlorothiazide Stada contains two active substances, olmesartan medoxomil and hydrochlorothiazide, which are used to treat high blood pressure (hypertension):
Olmesartan/hydrochlorothiazide will only be given to you if treatment with olmesartan medoxomil alone has not adequately controlled your blood pressure. The combined administration of both active substances in olmesartan/hydrochlorothiazide contributes to reducing blood pressure more than if each substance were administered alone.
You may already be taking medications to treat high blood pressure, but your doctor may believe it is necessary for you to take olmesartan/hydrochlorothiazide to lower it further.
High blood pressure can be controlled with medications like olmesartan/hydrochlorothiazide tablets. Your doctor has probably also recommended that you make some lifestyle changes to help lower your blood pressure (e.g., lose weight, stop smoking, reduce alcohol consumption, and reduce salt intake in your diet). Your doctor may also have recommended that you exercise regularly, such as walking or swimming. It is essential to follow your doctor's advice.
Do not take Olmesartan/Hydrochlorothiazide Stada:
If you think you have any of these conditions, or are unsure, do not take the tablets. Consult your doctor and follow their advice.
Warnings and precautions
Consult your doctor before starting to take Olmesartan/Hydrochlorothiazide Stada.
Before taking the tablets, tell your doctorif you are taking any of the following medications used to treat high blood pressure (hypertension):
Your doctor may need to adjust your dose and/or take other precautions:
If you are taking a converting enzyme inhibitor (ACE inhibitor) or aliskiren (see also the information under the headings “Do not take Olmesartan/Hydrochlorothiazide Stada” and “Warnings and precautions”).
Taking Olmesartan/Hydrochlorothiazide Stada with food, drinks, and alcohol
Olmesartan/hydrochlorothiazide can be taken with or without food.
Be careful when drinking alcohol while taking olmesartan/hydrochlorothiazide, as some people may feel dizzy or faint. If this happens, do not drink any alcohol, including wine, beer, or drinks with alcohol.
Black patients
As with other similar medications, the blood pressure-lowering effect of olmesartan/hydrochlorothiazide is somewhat less in black patients.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medication.
Pregnancy
You should inform your doctor if you are pregnant, think you may be pregnant, or plan to become pregnant. Your doctor will generally advise you to stop taking olmesartan/hydrochlorothiazide before becoming pregnant or as soon as you know you are pregnant, and will recommend that you take another medication instead of olmesartan/hydrochlorothiazide. It is not recommended to use olmesartan/hydrochlorothiazide at the start of pregnancy, and it should not be taken after the third month of pregnancy, as it may cause serious harm to your baby if taken after this time.
Breastfeeding
Inform your doctor if you are breastfeeding or plan to start breastfeeding. It is not recommended to use olmesartan/hydrochlorothiazide during breastfeeding, and your doctor may choose another treatment for you if you wish to breastfeed.
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medication.
Driving and using machines
You may feel drowsy or dizzy while being treated for high blood pressure. If this happens, do not drive or use machines until the symptoms have disappeared. Consult your doctor.
Olmesartan/Hydrochlorothiazide Stada contains lactose
If your doctor has told you that you have an intolerance to certain sugars, consult them before taking this medication.
Follow your doctor's instructions for taking this medication exactly. If you are unsure, consult your doctor or pharmacist again.
The recommended doseis one Olmesartan/Hydrochlorothiazide Stada 20 mg/12.5 mg tablet per day. If your blood pressure is not adequately controlled, your doctor may change the dose to one Olmesartan/Hydrochlorothiazide Stada 20 mg/25 mg tablet per day.
Swallow the tablets with water.
If possible, take your dose at the same time each day, e.g., at breakfast time. It is essential to continue taking olmesartan/hydrochlorothiazide until your doctor tells you to stop.
If you take more Olmesartan/Hydrochlorothiazide Stada than you should
If you take more tablets than you should or if a child accidentally ingests one or more tablets, contact your doctor or go to the emergency department of the nearest hospital immediately and take the medication package with you.
In case of overdose or accidental ingestion, consult your doctor, pharmacist, or call the Toxicology Information Service, phone 91 562 04 20, indicating the medication and the amount taken.
If you forget to take Olmesartan/Hydrochlorothiazide Stada
If you forget to take a dose, take your usual dose the next day. Do nottake a double dose to make up for forgotten doses.
If you stop taking Olmesartan/Hydrochlorothiazide Stada
It is essential to continue taking olmesartan/hydrochlorothiazide unless your doctor tells you to stop.
If you have any further questions about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine can cause adverse effects, although not all people suffer from them.
However, the following adverse effects may be serious, requiring urgent medical advice:
Olmesartan/hydrochlorothiazide is a combination of two active ingredients. The following information first describes the adverse effects reported so far with the olmesartan/hydrochlorothiazide combination (in addition to those already mentioned) and secondly, the known adverse effects of the two active ingredients separately.
These are other known adverse effects of olmesartan/hydrochlorothiazide so far:
If these effects occur, they are often mild and it is not necessary to interrupt treatment.
Common adverse effects (may affect up to 1 in 10 people)
Dizziness, weakness, headache, fatigue, chest pain, swelling of ankles, feet, legs, hands, or arms.
Uncommon adverse effects (may affect up to 1 in 100 people)
Rapid and intense heartbeat (palpitations), rash, eczema, vertigo, cough, indigestion, abdominal pain, nausea, vomiting, diarrhea, muscle cramps, and muscle pain, joint pain, arm and leg pain, back pain, erection problems in men, blood in urine.
Also, some changes in blood tests have been observed infrequently, including:
Increased levels of fat in the blood, increased urea or uric acid in the blood, increased creatinine, increased or decreased potassium levels in the blood, increased calcium levels in the blood, increased blood sugar, increased liver function test values.
Your doctor will monitor you with a blood test and tell you if you need to take any action.
Rare adverse effects (may affect up to 1 in 1,000 people)
Feeling of discomfort, altered consciousness, skin swelling (hives), acute kidney failure.
Also, some changes in blood test results have been observed rarely, including:
Increased blood urea nitrogen, decreased hemoglobin and hematocrit values.
Your doctor will monitor you with a blood test and tell you if you need to take any action.
Additional adverse effects reported with the use of olmesartan medoxomil or hydrochlorothiazide alone, but not in combination or at a higher frequency:
Olmesartan medoxomil:
Common adverse effects (may affect up to 1 in 10 people)
Bronchitis, cough, nasal congestion or secretion, sore throat, abdominal pain, indigestion, diarrhea, nausea, gastroenteritis, joint or bone pain, back pain, blood in urine, urinary tract infection, flu-like symptoms, pain.
Also, some changes in blood test results have been observed frequently, including:
Increased levels of fat in the blood, increased urea or uric acid in the blood, increased liver or muscle function.
Uncommon adverse effects (may affect up to 1 in 100 people)
Rapid allergic reactions that can affect the whole body and cause breathing problems, as well as a rapid drop in blood pressure that can lead to fainting (anaphylactic reactions), facial inflammation, angina (chest pain or discomfort known as angina pectoris), feeling of discomfort, allergic skin rash, itching, exanthema (skin rash), skin swelling (hives).
Also, some changes in blood test results have been observed infrequently, including:
Reduction in the number of a type of blood cell called platelets (thrombocytopenia).
Rare adverse effects (may affect up to 1 in 1,000 people)
Renal function deterioration, lack of energy.
Intestinal angioedema: swelling in the intestine that presents symptoms such as abdominal pain, nausea, vomiting, and diarrhea.
Also, some changes in blood test results have been observed rarely, including:
Increased potassium in the blood.
Hydrochlorothiazide:
Very common adverse effects (may affect more than 1 in 10 people)
Changes in blood tests, including: increased fat in the blood and uric acid levels.
Common adverse effects (may affect up to 1 in 10 people)
Feeling of confusion, abdominal pain, stomach discomfort, feeling of bloating, diarrhea, nausea, vomiting, constipation, glucose in urine (glucosuria).
Also, some changes in blood test results have been observed, including:
Increased creatinine, urea, calcium, and blood sugar levels, decreased chloride, potassium, magnesium, and sodium levels in the blood. Increased serum amylase (hyperamylasemia).
Uncommon adverse effects (may affect up to 1 in 100 people)
Decreased or lost appetite, severe breathing difficulties, anaphylactic skin reactions (hypersensitivity reactions), worsening of pre-existing myopia, erythema, skin reactions due to light sensitivity, itching, purple spots or patches on the skin due to small hemorrhages (purpura), skin swelling (hives).
Rare adverse effects (may affect up to 1 in 1,000 people):
Inflammation and pain of the salivary glands (sialadenitis), decreased number of white blood cells, decreased number of platelets in the blood, anemia, bone marrow depression, restlessness, depression, sleep problems, feeling of loss of interest (apathy), tingling and numbness (paresthesia), convulsions, yellowish perception of objects when looking at them, blurred vision, dry eyes, irregular heartbeat, inflammation of blood vessels, blood clots (thrombosis or embolism), lung inflammation, fluid accumulation in the lungs, pancreatitis, jaundice, infection in the gallbladder, symptoms of lupus erythematosus such as skin rash, joint pain, and cold hands and fingers, allergic skin reactions, skin peeling and blisters, non-infectious kidney inflammation (interstitial nephritis), fever, muscle weakness (sometimes causing movement disorders).
Very rare adverse effects (may affect up to 1 in 10,000 people):
Electrolyte imbalance that can cause an abnormally reduced level of chloride in the blood (hypochloremic alkalosis), intestinal obstruction (paralytic ileus).
Unknown adverse effects (frequency cannot be estimated from available data):
Decreased vision or eye pain due to high pressure (possible signs of fluid accumulation in the vascular layer of the eye (choroidal effusion) or acute angle-closure glaucoma).
Skin and lip cancer (non-melanoma skin cancer).
Reporting of adverse effects
If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect that is not listed in this leaflet. You can also report them directly through the Spanish Medicines Surveillance System for Human Use: https://www.notificaram.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.
Keep this medicine out of sight and reach of children.
No special storage conditions are required.
Do not use this medicine after the expiration date that appears on the packaging after "CAD". The expiration date is the last day of the month indicated.
Medicines should not be disposed of via wastewater or household waste. Deposit the packaging and medicines you no longer need at the SIGRE collection point in the pharmacy. Ask your pharmacist how to dispose of the packaging and medicines you no longer need. This will help protect the environment.
Composition of Olmesartan/Hydrochlorothiazide Stada
The active ingredients are olmesartan medoxomil and hydrochlorothiazide.
Each film-coated tablet contains 20 mg of olmesartan medoxomil and 12.5 mg of hydrochlorothiazide.
The other ingredients are: lactose monohydrate, microcrystalline cellulose, crospovidone, anhydrous colloidal silica, magnesium stearate, hypromellose, polyethylene glycol, titanium dioxide (E 171), and iron oxide (III) yellow/red (E 172).
Appearance of the product and package contents
Olmesartan/Hydrochlorothiazide Stada 20 mg/12.5 mg are film-coated tablets, beige in color, round, biconvex with a diameter of 8 mm.
The film-coated tablets are presented in blister packs of oPA-Al-PVC foil sealed with aluminum foil, containing 10, 14, 28, 30, 56, 60, 84, 90, 98, 100, 112, 156, or 168 tablets.
Not all pack sizes may be marketed.
Marketing authorization holder and manufacturer
Marketing authorization holder
Laboratorio STADA, S.L.
Frederic Mompou, 5
08960 Sant Just Desvern (Barcelona) Spain
Manufacturer
STADA Arzneimittel AG
Stadastrasse 2-18
61118 Bad Vilbel
Germany
or
Clonmel Healthcare Ltd.
Waterford Road
Clonmel, Co. Tipperary
Ireland
or
STADA M&D SRL
Str. Trascaului nr. 10,
Municipiul Turda,
Judet Cluj 401135,
Romania
This medicine is authorized in the Member States of the European Economic Area under the following names:
Spain Olmesartán/Hidroclorotiazida Stada 20 mg /12.5 mg film-coated tablets EFG
Ireland Olmesartan/Hydrochlorothiazide Clonmel 20 mg/12.5 mg film-coated tablets
Portugal Olmesartan + Hydrochlorothiazide Ciclum
Date of the last revision of this leaflet:January 2025
Detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/
.
The average price of OLMESARTAN/HYDROCHLOROTHIAZIDE STADA 20 mg/12.5 mg FILM-COATED TABLETS in October, 2025 is around 10.1 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for OLMESARTAN/HYDROCHLOROTHIAZIDE STADA 20 mg/12.5 mg FILM-COATED TABLETS – subject to medical assessment and local rules.